| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-03 |
| タイトル |
|
|
タイトル |
Donor lymphocyte infusion-based therapy for relapsed adult T-cell leukemia/lymphoma after HLA-haploidentical hematopoietic stem cell transplantation |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Donor lymphocyte infusion |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
HLA-haploidentical hematopoietic transplantation |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Adult T-cell leukemia/lymphoma |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Katsuoka, Shinichi
Itonaga, Hidehiro
Hashimoto, Miki
Sakamoto, Hikaru
Furumoto, Takafumi
Yamada, Yuichi
Kato, Takeharu
Horai, Makiko
Sato, Shinya
Ando, Koji
Nagai, Kazuhiro
Matsumoto, Nariyoshi
Sasaki, Daisuke
Hasegawa, Hiroo
Imaizumi, Yoshitaka
Yanagihara, Katsunori
Miyazaki, Yasushi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Donor lymphocyte infusion (DLI) combined with chemotherapy is an effective therapy for relapsed adult T-cell leukemia/lymphoma (ATL) after allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen (HLA)-matched related donor or matched unrelated donor. The 1-year incidence of ATL relapse is 28 % after HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide. However, the efficacy of DLI for relapsed ATL after haplo-HSCT remains unclear. Here, we present the case of a 61-year-old woman diagnosed with ATL who underwent haplo-HSCT from an HLA-haploidentical relative donor. On day +164 after transplantation, the patient experienced ATL relapse. Tacrolimus was tapered and discontinued on day +216; however, ATL progressed. Since the patient did not develop graft-versus-host disease (GVHD) after the discontinuation of tacrolimus, DLI following chemotherapy was performed for relapsed ATL. The patient achieved complete remission without severe GVHD after the 6th DLI treatment. This remission has been sustained for over 15 months with 13 DLI treatments. These results suggest the potential of DLI combined with chemotherapy as a treatment option for patients with relapsed ATL after haplo-HSCT. |
|
言語 |
en |
| 書誌情報 |
en : Transplant Immunology
巻 92,
p. art. no. 102262,
発行日 2025-06-24
|
| 出版者 |
|
|
出版者 |
Elsevier B.V. |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
09663274 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.trim.2025.102262 |
| 権利 |
|
|
権利情報 |
© 2025 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Transplant Immunology, 92, art. no. 102262; 2025 |
|
言語 |
en |
TI92_102262.pdf (700 KB)
